MetLife director awarded 639 shares as stock retainer grant
MetLife, Inc. reported a routine insider equity transaction involving one of its non-management directors.
Rhea-AI Filing Summary
MetLife, Inc. reported a routine insider equity transaction involving one of its non-management directors. On 01/02/2026, the director received 639 shares of MetLife common stock as part of non-management director retainer fees, at a price of $80.32 per share. After this award, the director beneficially owned 4,931 shares of MetLife common stock held directly.
The filing notes that MetLife’s compensation arrangements pay a portion of non-management director fees in company stock, and the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This reflects standard equity-based compensation rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 639 | $80.32 | $51K |
Footnotes (1)
- F1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
FAQ
What insider transaction did MetLife (MET) disclose in this Form 4?
MetLife disclosed that a non-management director received 639 shares of MetLife common stock on 01/02/2026 as part of director retainer compensation.
Was this MetLife (MET) insider transaction a purchase on the open market?
No. The explanation states that this was part of non-management director retainer fees paid in MetLife common stock, not an open-market trade.
AI-generated analysis. How Rhea-AI works. Not financial advice.